Pharmacogenetic angiogenesis profiling for first-line chemotherapy in patients with advanced gastric cancer

Cancer Invest. 2013 Jul;31(6):390-6. doi: 10.3109/07357907.2013.795580. Epub 2013 May 3.

Abstract

We retrospectively investigated germline polymorphisms in angiogenesis pathway genes (14 SNPs) and their correlation to clinical outcome (progression free survival and overall survival) in 128 patients with unresectable-advanced gastric carcinoma (AGC) treated with first-line chemotherapy. Our analysis revealed that Endostatin +4349 G>A polymorphism exhibited a worse progression free survival (PFS) and overall survival (OS) compared with the GG genotype. Significant OS difference was also observed in the endothelial nitric oxide synthase (eNOS)-786 T>C polymorphism. Hence, common germline variants in Endostatin and eNOS genes have predictive significance for clinical outcome and survivality in AGC patients treated with first-line chemotherapy.

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / genetics*
  • Adenocarcinoma / mortality
  • Adenocarcinoma / pathology
  • Adult
  • Aged
  • Disease-Free Survival
  • Endostatins / genetics*
  • Female
  • Gene Frequency
  • Genetic Association Studies
  • Humans
  • Induction Chemotherapy
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neovascularization, Pathologic / genetics*
  • Nitric Oxide Synthase Type III / genetics*
  • Polymorphism, Single Nucleotide*
  • Retrospective Studies
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / genetics*
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / pathology

Substances

  • Endostatins
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III